Shire has announced plans for a new haemophilia study in Ireland, to be carried out in collaboration with several local partners.
The company will ally with the Royal College of Surgeons Ireland, the Science Foundation Ireland and the Irish Haemophilia Society to launch iPATH, which will take place over a four-year period and seeks to identify new approaches to personalised treatment.
“Shire is partnering with the Royal College of Surgeons Ireland, the Science Foundation Ireland and the Irish Haemophilia Society to launch a new haemophilia study.“
Since haemophilia patients in Ireland already have data on the use of factor concentrates and bleeding rates collated by a single National Coagulation Centre, iPATH aims to use this information to better understand the underlying biology of the disease.
The aim is to develop a new approach to haemophilia care that can be tailored to individual needs and potentially be extended to the global haemophilia community, while it is also hoped that this study approach can be adapted for other diseases.
Peter Turecek, senior director for global medical affairs at Shire, said: "Through the iPATH study, we hope to uncover new solutions that build on and maximise the role of factor therapy and further personalise care for haemophilia patients."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical